We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Affirms Recommendation of Imatinib for GI Cancer
NICE Affirms Recommendation of Imatinib for GI Cancer
The UK’s healthcare cost agency affirmed its June recommendation to cover Novartis’ cancer drug Glivec as an adjuvant treatment for patients at high risk of post-surgery recurrence of gastrointestinal stromal tumors.